The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Wanbury Ltd

Wanbury Ltd

BSE 524212 · NSE WANBURY · ISIN INE107F01022 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹254.90

-2.67%

BSE close, 28 August 2026

Market cap

₹890.61 cr

3.5 cr shares · Micro cap

Free float

₹494.19 cr

as published

P/E · P/B

15.9× · 22.98×

EPS ₹16.00 · BV ₹11.09

FY25-26 rev / PAT

650.27 / 66.14

₹ cr, as filed

Filings, window

21

8 selected · 38%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹162.00 52-WK HIGH ₹360.00 ₹254.90 47% of range
Against 52-week high-29.2%
Against 52-week low+57.3%
Day change-2.67%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹16.00
Price / earnings15.93×
Price / book22.98×
Book value — derived, price ÷ P/B₹11.09
Return on equity144.24%
Operating margin10.02%
Net margin1.96%

Consistency check

P/B ÷ P/E, which must equal ROE
144.26%
ROE as published
144.24%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 165.58 3.24 0.93 10.02% 1.96%
Mar-26 · Q 164.58 21.71 7.33 16.07% 13.19%
FY25-26 650.27 66.14 20.55 16.01% 10.17%

Quarter on quarter

Revenue, quarter on quarter
+0.6%
Net profit, quarter on quarter
-85.1%
Operating margin, quarter on quarter
-605 bps

Disclosure profile 21 filings in the window

0 median 17.0 p75 · 25 sector max 52 21 64th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

21 filings · 8 selected · busiest 2026-08-11

Filing rhythm · the twelve most recent

2026-08-132026-10-09

SelectedProcedural

Filings

21 in the window · 14 earlier on record

  1. 9 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 8 October 2026 ·

    Press Release

    Press Release / Media Release

    Press Release regarding filing new Drug Master File (DMF) in South Africa for Tramadol HC1 API.

    Company Update / Press Release / Media Release View filing →

  3. 29 September 2026 ·

    Trading Window

    Closure of Trading Window

    Trading Window Closure for the Quarter ended 30th September, 2026.

    Insider Trading / SAST / Closure of Trading Window View filing →

  4. 25 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer Report and Voting Results

    AGM/EGM / AGM View filing →

  5. 24 September 2026 ·

    Change in Management

    Change in Management

    Change in Management

    Company Update / Change in Management View filing →

  6. 24 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 38th Annual General Meeting of the Company held on Thursday, September 24, 2026 through VC/OAVM

    AGM/EGM / AGM View filing →

  7. 2 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.

    Company Update / Newspaper Publication View filing →

  8. 31 August 2026 ·

    Book Closure

    Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM).

    The register of members and share transfer books of the Company will remain closed from Friday, 18 September, 2026 to Thursday, 24 September, 2026 (both days inclusive) for the purpose ....

    Corp. Action / Book Closure View filing →

  9. 31 August 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.

    Others / Reg. 34 (1) Annual Report View filing →

  10. 31 August 2026 ·

    AGM / EGM

    Annual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited.

    Notice of the 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).

    AGM/EGM / AGM View filing →

  11. 28 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M.

    Company Update / Newspaper Publication View filing →

  12. 13 August 2026 ·

    Press Release

    Press Release / Media Release

    Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.

    Company Update / Press Release / Media Release View filing →

  13. 11 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Outcome of the Board Meeting held on August 11, 2026

    Company Update / Allotment of ESOP / ESPS View filing →

  14. 11 August 2026 ·

    Press Release

    Press Release / Media Release

    Press Release on Un-audited Financial Results for the quarter ended 30th June, 2026

    Company Update / Press Release / Media Release View filing →

  15. 11 August 2026 ·

    Change in Management

    Change in Management

    Outcome of the Board Meeting held on August 11, 2026

    Company Update / Change in Management View filing →

  16. 11 August 2026 ·

    Results

    Financial Results For The First Quarter Ended 30Th June, 2026

    Financial Results for the first quarter ended 30th June, 2026

    Result / Financial Results View filing →

  17. 11 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of The Board Meeting Held On August 11, 2026

    Outcome of the Board Meeting held on August 11, 2026

    Board Meeting / Outcome of Board Meeting View filing →

  18. 3 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Wanbury Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....

    Board Meeting / Board Meeting View filing →

  19. 30 July 2026 ·

    Press Release

    Press Release / Media Release

    Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs

    Company Update / Press Release / Media Release View filing →

  20. 22 July 2026 ·

    General

    Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Company's Facility At Tanuku, West Godavari District, Andhra Pradesh

    Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company's Facilty.

    Company Update / General View filing →

  21. 20 July 2026 ·

    General

    Intimation Of Completion Of Inspection By The United States Food And Drug Administration (USFDA) At The Company's Facility At Tanuku, West Godavari District, Andhra Pradesh

    A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, ....

    Company Update / General View filing →

RSS feed for Wanbury Ltd · the 50 most recent filings